昊海生科(688366.SH)半年度淨利潤預增699.21%至808.19%
格隆匯6月25日丨昊海生科(688366.SH)公佈,預計2021年半年度實現歸屬於母公司所有者的淨利潤為人民幣2.2億元至2.5億元,與上年同期相比,將增加人民幣19247.28萬元至22247.28萬元,同比增長699.21%至808.19%。
預計歸屬於母公司所有者扣除非經常性損益後的淨利潤為人民幣2.1億元至2.4億元,與上年同期相比,將增加人民幣20217.01萬元至23217.01萬元,同比增長2582.03%至2965.17%。
公司2021年上半年業績較上年同期增長的主要原因系2020年上半年新冠疫情導致公司主要產品的銷售受到重大影響。2021年上半年,國內疫情得到有效控制,經濟回暖,公司主要產品的國內市場需求得到恢復並實現增長。同時,公司持續開展各類市場和營銷活動,擴大品牌知名度和影響力,報吿期內,公司產品特別是新產品的銷售較上年同期有較大幅度增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.